The cannabidiol market has grown robustly in recent years, signaling a transformative shift in global consumer wellness trends.
• The market size surged from $12.94 billion in 2024 to $17.85 billion in 2025, reflecting a remarkable CAGR of 37.9%.
The historic growth can be attributed to a changing regulatory landscape, leading to increased legalization of CBD, growth in public awareness of CBD's potential health benefits, medical research supporting CBD's use in treating various health conditions, emergence of diverse product categories including CBD-infused foods, beverages, and skincare and increased availability of CBD products through retail and e-commerce channels.
The cannabidiol market is on the course to witness monumental expansion in the coming years.
• By 2029, the market size is expected to skyrocket to $58.98 billion at a robust CAGR of 34.8%.
The predicted growth is backed by factors such as global legalization and harmonization of CBD products, cutting-edge pharmaceutical research and development for FDA-approved CBD medications, heightened consumer interest in CBD for mental health and relaxation, expansion of pet CBD market and veterinary applications, and growth of the hemp industry for CBD production.
Growing acceptance of CBD products powered by government approvals is fuelling the expansion of the cannabidiol market. CBD, derived from Cannabis Sativa, forms the backbone of various consumer products and therapies. Governments across the globe have recognized cannabidiol's potential utility for numerous medical conditions, leading to a surge in lawful marketing of CBD-driven products. For instance, in January 2022, the Therapeutic Goods Administration, an Australia-based medicine and therapeutic regulatory agency, approved around 210,000 SAS Category B applications for unapproved medicinal cannabis products.
The cannabidiol market can be segmented as follows –
1) By Product: Oil, Tinctures, Suppository, Transdermal Patches, Vape Oil, Isolates, Creams and Roll-on, Capsules, Tablet, Other Products
2) By Source: Marijuana, Hemp
3) By Treatment: CBD Oil, Supplements
4) By Application: Medical, Personal Use, Pharmaceuticals, Wellness
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Stores, Other Distribution Channels
Currently, prominent companies in the cannabidiol market are focusing on developing non-psychotropic products, which do not induce psychoactive effects. For instance, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical manufacturing company, launched Clasepi, a non-psychotropic CBD product for epilepsy treatment. Endorsed by DCGI, Clasepi aims to manage seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex in patients aged one year and older.
Major companies driving innovation in the cannabidiol market include:
• Endoca BV
• Cannoid LLC
• Medical Marijuana Inc.
• Folium Biosciences
• Elixinol Global Limited
• NuLeaf Naturals LLC
• Isodiol International Inc.
• Pharmahemp d.o.o.
• Canopy Growth Corp.
• CV Sciences Inc.
In 2024, North America was the largest region in the cannabidiol market. However, Asia-Pacific is projected to be the fastest-growing region during the forecast period. Other regions covered in the report include Western Europe, Eastern Europe, South America, the Middle East, and Africa.